~~<i id='288A687D0B'><strike id='288A687D0B'><tt id='288A687D0B'><pre id='288A687D0B'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

knowledge

author：comprehensive 2025-10-01 11:02:01 - browse：3984

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Cigna, Humana reportedly in talks to merge

explore

hotspot

Wikipedia

knowledge

leisure time

AdobeAnewstudypublishedWednesdayinJAMASurgerysuggeststhatpatientstreatedbyfemalesurgeonshavelowerrat

WSS

Takeda, Janssen join wearable maker to measure scratching

With clinical trial data readouts, here's how to spot spin

The EPA's new lead rule: How one expert crunched the numbers

Medicare to cover more brain scans related to Alzheimer’s drugs

The EPA's new lead rule: How one expert crunched the numbers

European regulators consider appeal over Amylyx ALS drug

hotspot

knowledge

explore

Virginia high school admissions case could be legal follow

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

Malaria cases in Florida and Texas: Here’s what you need to know

Takeda, Janssen join wearable maker to measure scratching

Hepatitis C has a cure — but many Americans still lack access to it

Nick Jonas talks about managing diabetes along with his career

New air purifier tech could be key to improving indoor air quality

The EPA's new lead rule: How one expert crunched the numbers

BioMarin wins approval for gene therapy to treat hemophilia A

As biotech industry slumps, bioscience job market is upside down

hotspot

Readout LOUD podcast: Merger Mondays, Ozempic panic

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

The EPA's new lead rule: How one expert crunched the numbers

Takeaways from AdvaMed, the largest medical devices conference

Diagnostic tests are hitting their mathematical limits

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

Wikipedia

Wikipedia

knowledge

leisure time